Unidentified Analyst: It does. And then I know you keep saying — referring to smaller animals. But isn’t the long-term intention to be on bigger animals as well or –?
John Lai: No, we started off on the equine because that’s an easy market for us. Because the veterinary doctors see the results right away. While when you’re dealing with small animals, they like to have the clinical data to support whatever statements we can make. Plus, when they inject a dog, they may not see that dog for a year — or six months to a year for the next checkup before they realize how well the dog is doing. So it’s a much longer time adoption for small animals, but the market is significantly larger. So there’s about 10 million horses in the United States, 83 million dogs in the United States, and about 60 million cats in the United States.
Unidentified Analyst: Okay. Awesome. Thank you.
John Lai: Okay.
Operator: [Operator Instructions]. I have a raised hand from a phone number ending in 4735. Please go ahead.
John Lai: Hello.
Unidentified Analyst : Hello, can you hear me okay?
John Lai: Yup.
Unidentified Analyst : Oh, hi, John. This is .
John Lai: Hi.
Unidentified Analyst : I’ve got a question. You had referred to something that I’m not familiar with because I’m relatively new to this field. It was called NSAIDs or NSAIDs. What was —
John Lai: NSAIDs, yeah. So that’s the standard treatment that veterinary doctor gives. It’s a basically an anti-inflammatory.
Unidentified Analyst : Okay.
John Lai: So with humans, it’s like —
Bob Folkes: Advil.
John Lai: Naproxen or something.
Bob Folkes: Advil.
John Lai: Advil, yeah. Thank you. Yeah.
Unidentified Analyst : Okay, got it. How do you spell that?
John Lai: The NSAIDs?
Unidentified Analyst : Yes. How do you spell it?
John Lai: Oh, N-S-A-I-D.
Unidentified Analyst : Okay. Great. Yeah, thanks. I appreciate that. You referred to it more than once, so I thought, what is that?
John Lai: Okay, no problem.
Unidentified Analyst : And do you have an update on human trials?
John Lai: No. We stated that on the human side, we’d done the necessary reviews of what the outside experts are telling us from a timetable. And then we would eventually, hopefully soon, announce our advisory team that’s experts in this area, to give recommendations the path to go. Because the human trials — so if you look at the OA market for humans on a global basis, about 240 billion a year as an addressable market. So to go through the human side, it’s significantly more expensive, obviously. But we would not raise money within PetVivo Holdings. We would always raise it within the subsidiary, so it won’t impact PetVivo’s share structure or expenses. And actually, when we do raise money on that side, the overall operating expenses from PetVivo Holdings, the parent itself, would actually reduce a little.
Unidentified Analyst: Okay. That sounds great. Thank you.
John Lai: Yup.
Operator: [Operator Instructions]. All right. No further questions. Thank you. This concludes our conference for today. Thank you for your participation, and you can find any information on the company site.
